Development of immunostimulatory virotherapy using non-transmissible Sendai virus-activated dendritic cells

Yoneyama, Yoshio; Ueda, Yasuji; Akutsu, Yasunori; Matsunaga, Akinao; Shimada, Hideaki; Kato, Tomonori; Kubota-Akizawa, Megumi; Okano, Shinji; Shibata, Satoko; Sueishi, Katsuo; Hasegawa, Mamoru; Ochiai, Takenori; Yonemitsu, Yoshikazu

doi:10.1016/j.bbrc.2007.01.132

Cited by 22 publications

(56 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5,6 To overcome the current limitation of this mode, we recently developed a new concept, 'immunostimulatory virotherapy', using rSeVs, which are recombinant virus-based immune boosters for DCs. 14,15 DCs activated by an rSeV have shown apparently superior antitumor effects on several tumor types compared with those seen by DCs treated with conventional stimuli, including lipopolysaccharide; they have also been shown not to lose their phago/pinocytotic activity, 15 and therefore an i.t. injection of rSeV-DCs without exposure to tumor antigen ex vivo evoked tumor-specific antitumor immunity.…”

Section: Discussionmentioning

confidence: 99%

“…These findings were similar to those of our earlier studies using B16 melanoma 14 and SCCVII squamous cell carcinoma. 15 To optimize the dose of DC-based immunotherapy that was activated by ts-rSeV/dF-null (ts-rSeV/dF-DCs), we first determined the effective dose of DCs to dermally implanted c1300 neuroblastomas in the abdominal wall of A/J female mice. We here administered ts-rSeV/dFDCs without antigen pulsation i.t., because this injection route showed an optimal antitumor effect against both B16F10 melanoma 14 and SCCIIV squamous cell carcinoma 15 in our earlier studies.…”

Section: C1300 Neuroblastoma Is Highly Resistant To Dc-based Immunothmentioning

confidence: 99%

“…15 To optimize the dose of DC-based immunotherapy that was activated by ts-rSeV/dF-null (ts-rSeV/dF-DCs), we first determined the effective dose of DCs to dermally implanted c1300 neuroblastomas in the abdominal wall of A/J female mice. We here administered ts-rSeV/dFDCs without antigen pulsation i.t., because this injection route showed an optimal antitumor effect against both B16F10 melanoma 14 and SCCIIV squamous cell carcinoma 15 in our earlier studies. At the same time, the therapeutic effect against c1300 was directly compared with that against B16F10 melanoma.…”

Section: C1300 Neuroblastoma Is Highly Resistant To Dc-based Immunothmentioning

confidence: 99%

“…15 rSeV is a novel and powerful gene transfer modality as a cytoplasmic gene expression system [16][17][18] that leads DCs to highly activated/mature state through a DExD/H-box RNA helicase, retinoic acid-inducible gene-I (RIG-I). 19,20 Therefore, we hypothesized that rSeV-activated DCs might enhance antitumor immunity against less immunogenic c1300 neuroblastoma.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Complete elimination of established neuroblastoma by synergistic action of γ-irradiation and DCs treated with rSeV expressing interferon-β gene

et al. 2008

View full text Add to dashboard Cite

Dendritic cell (DC)-based immunotherapy has been investigated as a new therapeutic approach to intractable neuroblastomas; however, only limited clinical effect has been reported. To overcome the relatively low sensitivity of neuroblastomas against immunotherapy, we undertook a preclinical efficacy study to examine murine models to assess the combined effects of g-irradiation pretreatment and recombinant Sendai virus (ts-rSeV/dF)-mediated murine interferon-b (mIFN-b) gene transfer to DCs using established c1300 neuroblastomas. Similar to intractable neuroblastomas in the clinic, established c1300 tumors were highly resistant to monotherapy with either g-irradiation or DCs activated by tsrSeV/dF without transgene (ts-rSeV/dF-null) that has been shown to be effective against other murine tumors, including B16F10 melanoma. In contrast, immunotherapy using DCs expressing mIFN-b through ts-rSeV/dF (ts-rSeV/dF-mIFNbDCs) effectively reduced tumor size, and its combination with g-irradiation pretreatment dramatically enhanced its antitumor effect, resulting frequently in the complete elimination of established c1300 tumors 7-9 mm in diameter, in a high survival rate among mice, and in the development of protective immunity in the mice against rechallenge by the tumor cells. These results indicate that the combination of tsrSeV/dF-mIFNb-DCs with g-irradiation is a hopeful strategy for the treatment of intractable neuroblastomas, warranting further investigation in the clinical setting.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: C1300 Neuroblastoma Is Highly Resistant To Dc-based Immunothmentioning

confidence: 99%

Section: C1300 Neuroblastoma Is Highly Resistant To Dc-based Immunothmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Complete elimination of established neuroblastoma by synergistic action of γ-irradiation and DCs treated with rSeV expressing interferon-β gene

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Various methods are used to activate DCs, including tumor cell lysates, CpG-oligodeoxynucleotide (CpG-ODN), cytokines and viral vectors. [25][26][27][28][29] Several groups have reported that viral vectors, including adenoviral and retroviral vectors, infect DCs and subsequently, infected DCs express tumor antigens and undergo maturation. Tumor growth is inhibited by inoculation of such tumor antigen-expressing DCs in tumor-bearing mice.…”

Section: Discussionmentioning

confidence: 99%

Induction of antitumor immunity against mouse carcinoma by baculovirus-infected dendritic cells

et al. 2010

View full text Add to dashboard Cite

A dendritic cell (DC) vaccine strategy has been developed as a new cancer immunotherapy, but the goal of complete tumor eradication has not yet been achieved. We have previously shown that baculoviruses potently infect DCs and induce antitumor immunity against hepatomas in a mouse model. Baculovirus-infected, bone marrow-derived DCs (BMDCs) display increased surface expression of costimulatory molecules, such as CD80, CD86 and major histocompatibility complex (MHC) classes I and II, and secrete interferons and other proinflammatory cytokines. In this study, we evaluated the induction of antitumor immunity in mice by baculovirus-infected BMDCs against lung cancer and melanoma. After treatment with baculovirus-infected BMDCs, murine lung tumors caused by Lewis lung carcinoma (LLC) cells were significantly reduced in size, and the survival of the mice was improved. In addition, experiments using a melanoma mouse model showed that baculovirus-infected BMDCs inhibited tumor growth and improved survival compared with controls. Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) and creatinine levels remained normal in baculovirus-infected BMDC-treated mice. Our findings show that baculovirus-infected DCs induce antitumor immunity and pave the way for the use of this technique as an effective tool for DC immunotherapy against malignancies.

show abstract

Carbon‐ion beam treatment induces systemic antitumor immunity against murine squamous cell carcinoma

Matsunaga

Ueda

Yamada³

et al. 2010

Cancer

Self Cite

View full text Add to dashboard Cite

BACKGROUND: Carbon-ion beam (CIB) treatment is a powerful tool for controlling primary tumors in the clinical setting. However, to date, few clinical or experimental studies have investigated the effects of CIB treatment on tumor recurrence and antitumor immunity. METHODS: A multiple challenge test was performed using syngenic and nude mouse models of a poorly immunogenic squamous cell carcinoma cell line (SCCVII) after CIB treatment at a clinically available dose (77 kiloelectron volts [keV]/lm) to primary tumors. To further examine changes in antitumor immunity in this model, the authors used dendritic cell (DC)-based immunotherapy. RESULTS: In a syngenic model, CIB treatment itself resulted not only in efficient elimination of the primary tumor but also in a dramatic reduction of tumor formation after secondary tumor challenge at a contralateral site (P < .0001). Conversely, CIB treatment eliminated neither the primary nor the secondary tumor in nude mice. This antitumor effect produced by CIB treatment was enhanced significantly by combining it with DC immunotherapy (P ¼ .0007). Combined CIB and DC treatment induced more intense cytolytic activity than CIB in a chromium-release assay. The third challenge tests, which included challenge with a third-party tumor cell line (FM3A) and effector depletion, revealed that the antitumor effects were the results of tumor-specific, long-lasting antitumor immunity through CD8-positive T lymphocytes. CONCLUSIONS: To the authors' knowledge, this is the first demonstration of strong antitumor immunity induced by CIB treatment in a dermal tumor, and this effect was enhanced by combining it with DC-based immunotherapy. The authors concluded that this combination warrants further investigation as a promising modality for the prevention of tumor recurrence. Cancer 2010;116;3740-8.

show abstract

Development of immunostimulatory virotherapy using non-transmissible Sendai virus-activated dendritic cells

Cited by 22 publications

References 25 publications

Complete elimination of established neuroblastoma by synergistic action of γ-irradiation and DCs treated with rSeV expressing interferon-β gene

Complete elimination of established neuroblastoma by synergistic action of γ-irradiation and DCs treated with rSeV expressing interferon-β gene

Induction of antitumor immunity against mouse carcinoma by baculovirus-infected dendritic cells

Carbon‐ion beam treatment induces systemic antitumor immunity against murine squamous cell carcinoma

Contact Info

Product

Resources

About